Jpmorgan Chase & CO Regenxbio Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RGNX
# of Institutions
196Shares Held
43MCall Options Held
104KPut Options Held
478K-
Black Rock Inc. New York, NY8.61MShares$62.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.89MShares$35.4 Million3.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$31.6 Million0.0% of portfolio
-
State Street Corp Boston, MA2.78MShares$20.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.35MShares$9.76 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $313M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...